Psoriasis Cure Now, a nonprofit patient advocacy group, today reported that biotech and pharmaceutical companies are investigating a record 70 potential new treatments for psoriasis and psoriatic arthritis. The data, culled from published reports and clinical trial recruitment Web sites, shows continued, strong business interest in the psoriasis market. A New York Times article last week called into question the profitability of the psoriasis sector, lighting up psoriasis message boards with concerns that the psoriasis drug pipeline could dry up. The full (and free) report of psoriasis treatments under clinical development is available on the Psoriasis Cure Now Web site: www.psoriasis-cure-now.org/hope.php.